Hyperviscosity Syndrome & Leukostasis Management

Algorithm Steps

1. ▶

   Start

   Suspected Hyperviscosity or Leukostasis

   Symptoms of blood hyperviscosity in hematologic malignancy

   1. ◆

      Decision

      Determine Type of Hyperviscosity

      Protein-mediated vs cellular

      • PARAPROTEIN-MEDIATED:
      • • Waldenström macroglobulinemia (IgM)
      • • Multiple myeloma (IgA, IgG3)
      • • Cryoglobulinemia
      • CELLULAR (LEUKOSTASIS):
      • • AML with WBC >100,000
      • • ALL with WBC >100,000-400,000
      • • CML blast crisis
      1. ●

         Action

         Recognize Clinical Features

         Both types have overlapping symptoms

         • NEUROLOGIC: Headache, confusion, visual changes, stupor
         • VISUAL: Blurred vision, diplopia, retinal hemorrhages
         • BLEEDING: Mucosal bleeding, epistaxis
         • PULMONARY: Dyspnea, hypoxia (esp. leukostasis)
         • CARDIAC: Heart failure symptoms
         • Fundoscopy: 'sausage-link' or 'boxcar' retinal veins
         1. ●

            Action

            Paraprotein Hyperviscosity

            IgM most common (Waldenström)

            • Measure serum viscosity (normal 1.4-1.8 cP)
            • Symptoms typically at >4-5 cP
            • IgM: viscosity rises steeply with concentration
            • Quantify paraprotein level
            • Check cryoglobulins (keep sample warm)
            1. ●

               Action

               Plasmapheresis

               First-line for paraprotein hyperviscosity

               • ASFA Category I indication
               • 1-1.5 plasma volume exchange
               • Daily until symptoms resolve
               • Uses albumin replacement (FFP if bleeding)
               • Reduces IgM by 30-50% per session
               • AVOID rituximab initially (IgM flare risk)
               1. ●

                  Action

                  Supportive Measures

                  For both types

                  • Aggressive IV hydration
                  • TLS prophylaxis (allopurinol/rasburicase)
                  • Avoid diuretics if possible
                  • Supplemental oxygen if hypoxic
                  • Monitor for DIC
                  • Correct coagulopathy with FFP/platelets
                  1. ●

                     Action

                     Initiate Cytoreductive Chemotherapy

                     Definitive treatment for underlying disease

                     • LEUKOSTASIS (AML/ALL):
                     • • Hydroxyurea 50-75 mg/kg/day as bridge
                     • • Induction chemotherapy ASAP
                     • WALDENSTRÖM:
                     • • Avoid rituximab initially (IgM flare)
                     • • Start with BTK inhibitor or bendamustine
                     • MYELOMA:
                     • • Bortezomib-based regimen
                     • • Rapid reduction in paraprotein
                     1. ●

                        Action

                        Monitor Response

                        Clinical and laboratory

                        • Symptom improvement (hours to days)
                        • Repeat viscosity measurements (paraprotein)
                        • Monitor WBC daily (leukostasis)
                        • Watch for tumor lysis syndrome
                        • Repeat apheresis if symptoms recur before chemo effect
                        1. ✓

                           Outcome

                           Hyperviscosity/Leukostasis Controlled

                           Continue treatment of underlying malignancy

         2. ●

            Action

            Leukostasis (Cellular)

            Clinical diagnosis in hyperleukocytosis

            • AML: Higher risk (larger, stickier blasts)
            • • Symptomatic at WBC >100,000
            • ALL: Lower risk (smaller blasts)
            • • Symptomatic at WBC >200,000-400,000
            • Pulmonary leukostasis: hypoxia, infiltrates
            • CNS leukostasis: confusion, stroke-like symptoms
            1. ●

               Action

               Leukapheresis

               Cytoreduction for leukostasis

               • ASFA Category II (AML) or III (ALL) indication
               • Reduces WBC by 30-60% per session
               • May need 1-2 sessions
               • Bridge to chemotherapy
               • Limited survival benefit but reduces early mortality
               • Not substitute for chemotherapy
            2. ⚠

               Warning

               ⚠️ AVOID RBC Transfusion

               In symptomatic leukostasis

               • RBC transfusion increases viscosity
               • Can worsen leukostasis symptoms
               • Keep Hgb <10 g/dL if symptomatic
               • Transfuse only if severely anemic AND asymptomatic